These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24298985)

  • 21. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
    Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
    Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
    Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
    Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation.
    Ambrose T; Sharkey LM; Louis-Auguste J; Rutter CS; Duncan S; English S; Gkrania-Klotsas E; Carmichael A; Woodward JM; Russell N; Massey D; Butler A; Middleton S
    Transplant Proc; 2016 Mar; 48(2):492-6. PubMed ID: 27109985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
    Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
    Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
    Silva JT; Pérez-González V; Lopez-Medrano F; Alonso-Moralejo R; Fernández-Ruiz M; San-Juan R; Brañas P; Folgueira MD; Aguado JM; de Pablo-Gafas A
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29226391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
    John GT; Manivannan J; Chandy S; Peter S; Fleming DH; Chandy SJ; Balakrishnan N; Krishnamurthy K; Kirubakaran MG; Jacob CK
    Transplant Proc; 2005 Dec; 37(10):4303-5. PubMed ID: 16387103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
    Chen F; Bando T; Hanaoka N; Fukuse T; Hasegawa S; Wada H
    Jpn J Thorac Cardiovasc Surg; 2005 Oct; 53(10):562-4. PubMed ID: 16279588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
    Waldman WJ; Knight DA; Lurain NS; Miller DM; Sedmak DD; Williams JW; Chong AS
    Transplantation; 1999 Sep; 68(6):814-25. PubMed ID: 10515382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
    Levi ME; Mandava N; Chan LK; Weinberg A; Olson JL
    Transpl Infect Dis; 2006 Mar; 8(1):38-43. PubMed ID: 16623819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is combination antiviral therapy for CMV superior to monotherapy?
    Drew WL
    J Clin Virol; 2006 Apr; 35(4):485-8. PubMed ID: 16387546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panresistant cytomegalovirus in a kidney transplant recipient.
    Yost SE; Echeverria A; Jie T; Kaplan B
    Pharmacotherapy; 2014 Jan; 34(1):e1-3. PubMed ID: 24277702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
    Goldsmith PM; Husain MM; Carmichael A; Zhang H; Middleton SJ
    Transplantation; 2012 Apr; 93(7):e30-2. PubMed ID: 22450598
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
    Fu L; Santhanakrishnan K; Al-Aloul M; Jones NP; Steeples LR
    Ocul Immunol Inflamm; 2020 Oct; 28(7):1152-1158. PubMed ID: 31621449
    [No Abstract]   [Full Text] [Related]  

  • 37. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports.
    Manfredi R; Mastroianni A; Coronado OV; Chiodo F
    Recenti Prog Med; 1996 Nov; 87(11):545-8. PubMed ID: 9122537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Mihm J; Leyking S; Dirks J; Smola S; Fliser D; Sester U; Sester M; Wilkens H; Rissland J
    J Clin Virol; 2016 Sep; 82():5-8. PubMed ID: 27389910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.